以岭药业(002603) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥2,358,232,707.77, a decrease of 6.52% compared to ¥2,522,632,691.84 in the same period last year[4] - Net profit attributable to shareholders increased by 7.25% to ¥325,953,296.25 from ¥303,927,918.74 year-on-year[4] - Basic and diluted earnings per share rose by 7.26% to ¥0.1951 from ¥0.1819 in the same quarter last year[4] - Total operating revenue for the current period is ¥2,358,232,707.77, a decrease of 6.5% from ¥2,522,632,691.84 in the previous period[18] - Net profit attributable to the parent company increased to ¥325,953,296.25, up 7.0% from ¥303,927,918.74 in the previous period[20] - The total comprehensive income for the current period is ¥324,101,020.55, compared to ¥301,886,529.06 in the previous period[20] Cash Flow - The net cash flow from operating activities surged by 190.67% to ¥340,097,107.41, compared to ¥117,005,271.96 in the previous year[4] - Cash generated from operating activities increased to ¥2,035,275,225.73, up from ¥1,936,876,740.92 in the previous period[22] - Cash inflow from operating activities totaled $2,180,849,648.91, compared to $1,991,079,544.74 in the previous year, reflecting a year-over-year increase[23] - Cash outflow from operating activities was $1,840,752,541.50, slightly decreased from $1,874,074,272.78[23] - The company reported a net exchange loss of ¥54,894.21 in other comprehensive income, compared to a loss of ¥33,169.55 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was positive, contributing $81,373.65 to the total[23] Assets and Liabilities - Total assets increased by 2.81% to ¥13,694,088,012.80 from ¥13,319,171,088.28 at the end of the previous year[4] - The company's equity attributable to shareholders grew by 3.19% to ¥10,549,386,134.31 from ¥10,223,487,732.27 at the end of last year[4] - Total liabilities increased to ¥3,167,894,326.54, compared to ¥3,117,078,422.57 in the previous period[16] - Non-current liabilities decreased slightly to ¥506,741,246.93 from ¥510,389,530.41 in the previous period[16] - The total liabilities include accounts payable of ¥1,766,550,464.18, down from ¥1,846,575,493.59, a decrease of approximately 4.3%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 185,292[11] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of shares, totaling 526,775,963 shares[11] - The second-largest shareholder, Wu Xiangjun, holds 20.81% with 347,728,119 shares, of which 260,796,089 shares are pledged[11] Inventory and Receivables - Accounts receivable increased by 31.17% to ¥1,607,442,791.61, primarily due to increased sales volume[8] - Inventory decreased to ¥1,385,508,236.24 from ¥1,746,380,345.14, reflecting a decline of approximately 20.7%[15] - Accounts receivable rose to ¥1,607,442,791.61 from ¥1,225,430,236.42, indicating an increase of about 31.1%[15] Investment Activities - The company experienced a 356.62% decline in cash flow from investing activities, resulting in a net outflow of ¥198,379,807.59, primarily due to reduced redemptions of financial products[9] - Total cash inflow from investment activities decreased to $280,127,334.14 from $1,481,130,024.34, indicating a decline in investment returns[23] - Cash received from investment recoveries was $280,000,000.00, a significant drop from $1,467,775,784.74 in the previous year[23] - Cash paid for investments was $439,800,000.00, down from $1,341,000,000.00, indicating reduced capital expenditures[23] Operational Insights - The company has ongoing development expenditures of ¥270,129,783.30, up from ¥262,797,369.23, showing an increase of about 2.4%[15] - The company has not reported any new product launches or significant market expansion strategies in the current quarter[13] - The company's cash flow management reflects a strategic focus on improving operational efficiency while navigating investment challenges[23]